New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Core Insights - LIXTE Biotechnology Holdings, Inc. announced that findings published in the journal Nature validate its ongoing clinical trials with the proprietary compound LB100 for Ovarian and Colorectal cancers [1][2] Group 1: Clinical Trials and Research Findings - A study led by Dr. Amir Jazaeri found that Ovarian Clear Cell Carcinoma (OCCC) patients with inactivating mutations in PPP2R1A had significantly better overall survival when treated with immune checkpoint blockade therapy [2][3] - Inactivating mutations in PPP2R1A reduce the enzymatic activity of PP2A, which is the target of LIXTE's LB-100, and these tumors showed increased interferon gamma response pathways associated with improved immune checkpoint responses [3] - LIXTE is conducting two clinical trials to investigate LB-100's activity in combination with checkpoint immunotherapy, one in collaboration with GSK for OCCC and another with Roche for colon cancer patients [4][5] Group 2: Company Overview and Future Directions - LIXTE is focused on developing new cancer therapies and has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity [6][7] - The company is pioneering a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for various cancer types [7]